Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biogen Idec buys analgesic developer Convergence for $200m+

This article was originally published in Scrip

Executive Summary

Biogen Idec has agreed to pay $200m up front and up to $475m in milestones to acquire the UK developer of drugs for neuropathic pain Convergence Pharmaceuticals. The target company's most promising pipeline drug is CNV1014802, which has yielded positive Phase II results for trigeminal neuralgia (TGN), an orphan condition characterized by excruciating face pain.

You may also be interested in...



Interview: C4XD Chief Sees Indivior Pact As First Of Many

The deal for an oral orexin-1 receptor antagonist which aims to treat addiction by targeting the craving process validates C4XD's strategy of out-licensing preclinical programs. CEO Clive Dix told Scrip more agreements will follow as the firm "is not a one-trick pony."

GSK Spin-Out NeRRe Raises £23m For NK Antagonists

New cash will fund further clinical testing of NeRRe's two neurokinin receptor antagonists for cough and hot flashes.

Titans Of Pharma 2022: Johnson & Johnson Pays Highest Exec Compensation Again

Infographic: A snapshot of executive compensation at the world’s biggest pharmaceutical companies. Explore our interactive dashboard and visualizations comparing remuneration packages with other key company metrics.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC027491

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel